FURTHER: A Global Study to Evaluate Furmonertinib in Patients with EGFR Mutant NSCLC Including Uncommon EGFR Mutations (FURMO-002).
Journal of Clinical Oncology(2024)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined